Kbc Group Nv Clovis Oncology, Inc. Transaction History

Kbc Group Nv

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 04, 2020	SELL	$3.77 - $11.0 $47,928 - $139,843	-12,713 Closed	0 $0
Q4 2019 Feb 11, 2020	SELL	$3.0 - $16.43 $123,813 - $678,082	-41,271 Reduced 76.45%	12,713 $133,000
Q3 2019 Nov 07, 2019	BUY	$3.93 - $15.35 $159,923 - $624,637	40,693 Added 306.17%	53,984 $212,000
Q1 2019 May 10, 2019	SELL	$17.66 - $30.28 $5.35 Million - $9.16 Million	-302,667 Reduced 95.79%	13,291 $0
Q4 2018 Jan 31, 2019	BUY	$11.63 - $32.67 $863,283 - $2.43 Million	74,229 Added 30.71%	315,958 $5.67 Million
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $4.35 Million - $7.33 Million	148,227 Added 158.53%	241,729 $0
Q2 2018 Aug 03, 2018	BUY	$42.06 - $62.4 $224,558 - $333,153	5,339 Added 6.06%	93,502 $0
Q1 2018 May 09, 2018	BUY	$50.12 - $67.72 $1.56 Million - $2.11 Million	31,151 Added 54.64%	88,163 $0
Q4 2017 Feb 07, 2018	BUY	$57.69 - $84.58 $942,827 - $1.38 Million	16,343 Added 40.19%	57,012 $0
Q3 2017 Nov 13, 2017	BUY	$67.17 - $84.81 $2.73 Million - $3.45 Million	40,669	40,669 $0

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.